Central Nervous System Agents
"Central Nervous System Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
| Descriptor ID |
D002491
|
| MeSH Number(s) |
D27.505.954.427
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Agents".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Agents".
This graph shows the total number of publications written about "Central Nervous System Agents" by people in this website by year, and whether "Central Nervous System Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Agents" by people in Profiles.
-
Di Trana A, Berardinelli D, Montanari E, Berretta P, Basile G, Huestis MA, Busard? FP. Molecular Insights and Clinical Outcomes of Drugs of Abuse Adulteration: New Trends and New Psychoactive Substances. Int J Mol Sci. 2022 Nov 23; 23(23).
-
Hanlon JT, Zhao X, Naples JG, Aspinall SL, Perera S, Nace DA, Castle NG, Greenspan SL, Thorpe CT. Central Nervous System Medication Burden and Serious Falls in Older Nursing Home Residents. J Am Geriatr Soc. 2017 Jun; 65(6):1183-1189.
-
Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine Infusions for Treatment Refractory Headache. Headache. 2017 Feb; 57(2):276-282.
-
Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S. How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine. Headache. 2016 Jul; 56(7):1194-200.
-
Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008 Nov 25; 71(22):1770-5.
-
Ermer JC, Shojaei A, Pennick M, Anderson CS, Silverberg A, Youcha SH. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. Curr Med Res Opin. 2007 May; 23(5):1067-75.
-
Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther. 1996 Dec; 60(6):601-7.
-
KOLOMEYER N. A clinical evaluation of mephentermine sulfate and pentylenetetrazol as stimulant therapy for the geriatric patient. J Am Geriatr Soc. 1958 May; 6(5):415-23.